EPICS: Global Perspectives in Gastrointestinal Malignancies in 2022 and Beyond

Latest therapeutic developments in GI cancer treatment and implications on individualized clinical decision-making. How will emerging data shape future treatment paradigms?

September 17 and 23, 2022

Faculty Chair

Tanios Bekaii-Saab, MD, FACP

Mayo Clinic Cancer Center, Phoenix, AZ, USA

Faculty Members

Christopher Lieu, MD
University of Colorado Cancer Center, Aurora, CO, USA

Joleen Hubbard, MD
Mayo Clinic, Rochester, MN, USA

Philip A. Philip, MD, PhD
Henry Ford Cancer Institute, Detroit, MI, USA

John H. Strickler, MD
Duke Cancer Center, Durham, NC, USA

Julien Taieb, MD, PhD
University of Paris, France

Gerald Prager, MD, PhD
University of Vienna, Austria

Chiara Cremolini, MD, PhD
University of Pisa, Italy

Alan P. Venook, MD
Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA

Scott Kopetz, MD, PhD, FACP
MD Anderson Cancer Center, Houston, TX, USA

Efrat Dotan, MD
Fox Chase Cancer Center, Philadelphia, PA, USA

Sample Report

Start discovering the insights

View Report


  • Metastatic Colorectal Cancer – Chemotherapy, Targeted Therapies, and Biomarker-Driven Treatments
  • Colorectal Cancer – Immunotherapy
  • Hepatocellular Carcinoma
  • Gastroesophageal Junction (GEJ) and Gastric Cancer
  • Rectal Cancer
  • Pancreatic Cancer and Biliary Tract Cancer

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.